ZHEJIANG YATAI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.13 CNY | -1.57% |
|
+5.39% | -27.04% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 8,911 | 3,450 | 2,012 | 2,404 | 2,640 | 2,421 |
| Enterprise Value (EV) 1 | 8,640 | 3,316 | 2,124 | 2,557 | 2,835 | 2,391 |
| P/E ratio | 42.6 x | -1.67 x | 75 x | -10.4 x | -19.7 x | -215 x |
| Yield | 0.3% | - | - | - | - | - |
| Capitalization / Revenue | 6.8 x | 4.86 x | 3.91 x | 7.63 x | 7.07 x | 5.76 x |
| EV / Revenue | 6.6 x | 4.68 x | 4.13 x | 8.12 x | 7.59 x | 5.68 x |
| EV / EBITDA | 30.3 x | -18.7 x | -69.8 x | -28.6 x | 1,150 x | 2,065 x |
| EV / FCF | -13 x | -60.3 x | -41.6 x | -32.2 x | -76.6 x | -37.9 x |
| FCF Yield | -7.7% | -1.66% | -2.4% | -3.1% | -1.31% | -2.64% |
| Price to Book | 3.55 x | 5.45 x | 3.05 x | 5.55 x | 8.77 x | 5.92 x |
| Nbr of stocks (in thousands) | 536,494 | 536,494 | 536,545 | 536,614 | 536,684 | 564,440 |
| Reference price 2 | 16.61 | 6.430 | 3.750 | 4.480 | 4.920 | 4.290 |
| Announcement Date | 4/26/19 | 3/13/20 | 3/26/21 | 4/29/22 | 4/24/23 | 3/30/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,310 | 709.3 | 514.4 | 315.1 | 373.4 | 420.6 |
| EBITDA 1 | 285.3 | -177 | -30.42 | -89.56 | 2.465 | 1.158 |
| EBIT 1 | 242.1 | -224.4 | -79.59 | -131.1 | -35.99 | -33.01 |
| Operating Margin | 18.49% | -31.63% | -15.47% | -41.61% | -9.64% | -7.85% |
| Earnings before Tax (EBT) 1 | 241.4 | -2,070 | 29.3 | -224.2 | -135.3 | -11.56 |
| Net income 1 | 207.8 | -2,069 | 27.27 | -228.3 | -132.7 | -11.88 |
| Net margin | 15.87% | -291.65% | 5.3% | -72.44% | -35.54% | -2.82% |
| EPS 2 | 0.3900 | -3.860 | 0.0500 | -0.4300 | -0.2500 | -0.0200 |
| Free Cash Flow 1 | -665.6 | -55.04 | -51.03 | -79.36 | -37.03 | -63.12 |
| FCF margin | -50.82% | -7.76% | -9.92% | -25.18% | -9.92% | -15% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | 0.0500 | - | - | - | - | - |
| Announcement Date | 4/26/19 | 3/13/20 | 3/26/21 | 4/29/22 | 4/24/23 | 3/30/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 112 | 153 | 194 | - |
| Net Cash position 1 | 271 | 133 | - | - | - | 30.9 |
| Leverage (Debt/EBITDA) | - | - | -3.669 x | -1.712 x | 78.77 x | - |
| Free Cash Flow 1 | -666 | -55 | -51 | -79.4 | -37 | -63.1 |
| ROE (net income / shareholders' equity) | 8.56% | -131% | 4.36% | -41.8% | -36.2% | -2.69% |
| ROA (Net income/ Total Assets) | 5.02% | -5.04% | -2.35% | -4.59% | -1.44% | -1.4% |
| Assets 1 | 4,143 | 41,050 | -1,158 | 4,968 | 9,246 | 850 |
| Book Value Per Share 2 | 4.680 | 1.180 | 1.230 | 0.8100 | 0.5600 | 0.7200 |
| Cash Flow per Share 2 | 1.000 | 2.200 | 1.680 | 1.530 | 1.410 | 1.180 |
| Capex 1 | 631 | 295 | 39.1 | 15.8 | 21.1 | 7.46 |
| Capex / Sales | 48.17% | 41.57% | 7.6% | 5.01% | 5.65% | 1.77% |
| Announcement Date | 4/26/19 | 3/13/20 | 3/26/21 | 4/29/22 | 4/24/23 | 3/30/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.04% | 263M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 002370 Stock
- Financials Zhejiang Yatai Pharmaceutical Co., Ltd.
